| scholarly article | Q13442814 |
| P2093 | author name string | A J Watson | |
| G P Margison | |||
| E S Newlands | |||
| J A Rafferty | |||
| J C Baer | |||
| A A Freeman | |||
| P2860 | cites work | Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine | Q24336908 |
| Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856) | Q24683819 | ||
| Repair of DNA containing O6-alkylguanine | Q28284603 | ||
| Expression of human O6-methylguanine-DNA methyltransferase in a DNA excision repair-deficient Chinese hamster ovary cell line and its response to certain alkylating agents | Q28324330 | ||
| New colorimetric cytotoxicity assay for anticancer-drug screening | Q29615418 | ||
| Phase I clinical trial of mitozolomide | Q33459771 | ||
| Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents | Q33689518 | ||
| Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine | Q34691516 | ||
| Expression of a human O6-alkylguanine-DNA-alkyltransferase cDNA in human cells and transgenic mice | Q35880142 | ||
| Plasma and tissue disposition of mitozolomide in mice | Q36027380 | ||
| DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal | Q37984292 | ||
| Upregulation of O6-alkylguanine-DNA-alkyltransferase expression and the presence of double minute chromosomes in alkylating agent selected Chinese hamster cells | Q41638659 | ||
| Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents | Q42019699 | ||
| Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent | Q42255336 | ||
| O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine | Q44138296 | ||
| O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary | Q48672550 | ||
| Use of a colorimetric microtiter (MTT) assay in determining the radiosensitivity of cells from murine solid tumors. | Q50894388 | ||
| Transfection of murine multi-potent haemopoietic stem cells with an E. coli DNA alkyltransferase gene confers resistance to the toxic effects of alkylating agents. | Q53525648 | ||
| In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. | Q54400288 | ||
| Formation of the cross-link 1-[N3-deoxycytidyl),2-[N1-deoxyguanosinyl]ethane in DNA treated with N,N'-bis(2-chloroethyl)-N-nitrosourea. | Q54513973 | ||
| Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. | Q55484775 | ||
| Antitumour imidazotetrazines--XVI. Macromolecular alkylation by 3-substituted imidazotetrazinones | Q69007066 | ||
| In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma | Q70014000 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | temozolomide | Q425088 |
| P304 | page(s) | 1299-1302 | |
| P577 | publication date | 1993-06-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells | |
| P478 | volume | 67 |
| Q33787022 | 2D-QSAR and 3D-QSAR Analyses for EGFR Inhibitors. |
| Q40069172 | 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity |
| Q35561443 | 4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine |
| Q33373492 | A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma |
| Q36667516 | A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer |
| Q41365343 | A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells |
| Q41720039 | Aberrant Kynurenine Signaling Modulates DNA Replication Stress Factors and Promotes Genomic Instability in Gliomas |
| Q62662280 | Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL) |
| Q36655704 | Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients |
| Q33405625 | Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience |
| Q41349090 | Chemoprotection of normal tissues by transfer of drug resistance genes |
| Q36463078 | Complications of a temozolomide overdose: a case report |
| Q37809861 | Current and emerging molecular targets in glioma |
| Q35095713 | Current and future strategies for the treatment of malignant brain tumors. |
| Q40967572 | Cytokinetics of a novel 1,2,3-triazene-containing heterocycle, 8-nitro-3-methyl-benzo-1,2,3,5-tetrazepin-4(3H)-one (NIME), in the human epithelial ovarian cancer cell line OVCAR-3. |
| Q43552493 | Debenzylation of O(6)-benzyl-8-oxoguanine in human liver: implications for O(6)-benzylguanine metabolism |
| Q36430966 | Design and mechanism of action of a novel cytotoxic 1,2,3-triazene-containing heterocycle, 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), in the human epithelial ovarian cancer cell line NIH:OVCAR-3 in vitro |
| Q73051563 | Determination of 8-oxoguanine in human plasma and urine by high-performance liquid chromatography with electrochemical detection |
| Q42046696 | Differential inactivation of mammalian and Escherichia coli O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine |
| Q39869690 | Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide |
| Q40596021 | Efficient retroviral vector targeting of carcinoembryonic antigen-positive tumors |
| Q36431304 | Enhancement by O6-benzyl-N2-acetylguanosine of N'-[2-chloroethyl]-N-[2-(methylsulphonyl)ethyl]-N'-nitrosourea therapeutic index on nude mice bearing resistant human melanoma |
| Q33385736 | Extended-schedule dose-dense temozolomide in refractory gliomas |
| Q90618650 | Glioblastoma Treatment Modalities besides Surgery |
| Q31994979 | High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma |
| Q35978302 | Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. |
| Q36619026 | Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in mice |
| Q73850206 | Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents |
| Q36671738 | Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. |
| Q39908793 | Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells |
| Q64269958 | Liposomal Taro Lectin Nanocapsules Control Human Glioblastoma and Mammary Adenocarcinoma Cell Proliferation |
| Q36812597 | Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection |
| Q48181924 | MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance. |
| Q35173837 | Mechanisms of anticancer drug resistance |
| Q36726010 | Mechanisms of chemoresistance to alkylating agents in malignant glioma |
| Q90164700 | Medical Management of Gastroenteropancreatic Neuroendocrine Tumors |
| Q37425078 | Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma |
| Q45889046 | Modulation of O6-alkylating agent induced clastogenicity by enhanced DNA repair capacity of bone marrow cells |
| Q33852965 | Monitoring pharmacokinetics of anticancer drugs: non-invasive investigation using magnetic resonance spectroscopy |
| Q43217464 | NICE verdict on Temozolomide: where next? |
| Q34090967 | Novel chemotherapeutic agents for the treatment of brain cancer |
| Q40464109 | O 6 -Alkylguanine-DNA Alkyltransferase: A Target for the Modulation of Drug Resistance |
| Q30444762 | O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas |
| Q35234429 | Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation |
| Q46017033 | Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. |
| Q46923024 | Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. |
| Q33344136 | Phase I study of fotemustine in pediatric patients with refractory brain tumors |
| Q33349020 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas |
| Q45139628 | Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas |
| Q44532454 | Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression |
| Q37262527 | Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme |
| Q24644727 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma |
| Q44390085 | Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates |
| Q57814961 | Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma |
| Q34994597 | Polymorphisms in DNA repair and environmental interactions |
| Q39993380 | Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro |
| Q34426355 | Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas |
| Q38019607 | Small-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugs. |
| Q40473972 | Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase |
| Q37355401 | Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line. |
| Q46213367 | Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia |
| Q39700247 | Targeted retroviral infection of tumor cells by receptor cooperation |
| Q43761368 | Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. |
| Q57569791 | Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group |
| Q33367496 | Temozolomide in resistant or relapsed pediatric solid tumors |
| Q91792247 | Temozolomide resistance in glioblastoma multiforme |
| Q37454341 | Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. |
| Q34675920 | Temozolomide-modulated glioma proteome: role of interleukin-1 receptor-associated kinase-4 (IRAK4) in chemosensitivity |
| Q34429383 | Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials |
| Q48836301 | The Charing Cross Hospital experience with temozolomide in patients with gliomas |
| Q91707540 | The role of interleukin-6-STAT3 signalling in glioblastoma |
| Q30442049 | Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas |
| Q37900207 | Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity |
| Q38055208 | Vemurafenib for the treatment of melanoma |
| Q54904068 | MaWi | described by source | P1343 |
Search more.